Roche: No new cost-cutting programs; Pfizer to build in Saudi Arabia;

> Roche chairman Franz Humer: "We don't need new [cost-cutting] programs but we will always pursue efficiency improvements." Story

> Pfizer ($PFE) follows Sanofi ($SNY) into Saudi Arabia, snagging a 65,000-square-meter tract in the King Abdullah Economic City for a manufacturing facility. Article

> A rise in OxyContin smuggling from Canada brings back to the U.S. the drug's earlier formulation, which lacks the more effective abuse deterrents of the one now in use. Story

> GlaxoSmithKline ($GSK) plans to invest $7 million in two production lines at a plant in Romania where it manufactures the antidepressant Seroxat and the HIV treatment Retrovir. Article

> China's drug regulator has begun inspections of overseas manufacturing plants. Article

> Controlled- and targeted-release specialist Intellipharmaceutics International says its Toronto oral solid dosage forms manufacturing facility has been dubbed "acceptable" following a cGMP and pre-approval inspection by the FDA. Intellipharmaceutics release

> Quebec-based IntelGenx ($IGXT) has won FDA approval for depression treatment CPI-300, a 450-mg formulation of the Wellbutrin XL API, bupropion hydrochloride. IntelGenx release

> Pfizer ($PFE) continues to push for the sale of two upstate New York plants, in Rouses Point and Chazy, in "an extremely challenging and slow marketplace." Story

> Modernized traditional Chinese medicine appears to be gaining in popularity: Bohai Pharmaceuticals ($BOPH) reports a 78% revenue leap to $30 million for the latest quarter. Bohai release


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.